{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:30:18Z","timestamp":1787927418899,"version":"build-2784847793"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008593","name":"European Respiratory Society","doi-asserted-by":"publisher","award":["4,6"],"award-info":[{"award-number":["4,6"]}],"id":[{"id":"10.13039\/100008593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020568","name":"Roivant Sciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020568","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.cct.2025.108078","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:30:50Z","timestamp":1757550650000},"page":"108078","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Design of RESOLVE Lung, a multinational Phase 2, randomized, placebo-controlled trial of the anti-GM-CSF monoclonal antibody namilumab in patients with chronic pulmonary sarcoidosis"],"prefix":"10.1016","volume":"158","author":[{"given":"Bernt","family":"van den Blink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal M.","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayes M.","family":"Dansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies S.","family":"Wijsenbeek-Lourens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surinder S.","family":"Birring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Baughman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore F.","family":"Reiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2025.108078_bb0005","article-title":"New advances in the management of pulmonary sarcoidosis","volume":"367","author":"Culver","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.cct.2025.108078_bb0010","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/MCP.0000000000000080","article-title":"Morbidity and mortality in sarcoidosis","volume":"20","author":"Gerke","year":"2014","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.cct.2025.108078_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.545413","article-title":"Treatment of sarcoidosis: a multidisciplinary approach","volume":"11","author":"Gerke","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cct.2025.108078_bb0020","article-title":"Sarcoidosis: updates on therapeutic drug trials and novel treatment approaches","volume":"9","author":"Obi","year":"2022","journal-title":"Front Med (Lausanne)."},{"key":"10.1016\/j.cct.2025.108078_bb0025","first-page":"325","article-title":"Current and emerging pharmacological treatments for sarcoidosis: a review","volume":"7","author":"Beegle","year":"2013","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.cct.2025.108078_bb0030","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-term systemic corticosteroid exposure: a systematic literature review","volume":"39","author":"Rice","year":"2017","journal-title":"Clin. Ther."},{"key":"10.1016\/j.cct.2025.108078_bb0035","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.rmed.2016.04.011","article-title":"Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab","volume":"115","author":"Crommelin","year":"2016","journal-title":"Respir. Med."},{"key":"10.1016\/j.cct.2025.108078_bb0040","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41577-020-0357-7","article-title":"GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches","volume":"20","author":"Lang","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cct.2025.108078_bb0045","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190945","article-title":"GM-CSF in inflammation","volume":"217","author":"Hamilton","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cct.2025.108078_bb0050","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.immuni.2019.03.022","article-title":"GM-CSF, IL-3, and IL-5 family of cytokines: regulators of inflammation","volume":"50","author":"Dougan","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.cct.2025.108078_bb0055","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.4049\/jimmunol.157.11.5118","article-title":"Differential effects of macrophage- and granulocyte-macrophage colony-stimulating factors on cytokine gene expression during rat alveolar macrophage differentiation into multinucleated giant cells (MGC): role for IL-6 in type 2 MGC formation","volume":"157","author":"Lemaire","year":"1996","journal-title":"J. Immunol."},{"key":"10.1016\/j.cct.2025.108078_bb0060","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1038\/cdd.2013.130","article-title":"A novel subset of helper T cells promotes immune responses by secreting GM-CSF","volume":"20","author":"Zhang","year":"2013","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.cct.2025.108078_bb0065","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1038\/s41467-022-30615-x","article-title":"Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis","volume":"13","author":"Damsky","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cct.2025.108078_bb0070","article-title":"The role of diverse immune cells in sarcoidosis","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cct.2025.108078_bb0075","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/bjd.17195","article-title":"Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody","volume":"180","author":"Papp","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.cct.2025.108078_bb0080","doi-asserted-by":"crossref","first-page":"e537","DOI":"10.1016\/S2665-9913(24)00099-7","article-title":"Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"6","author":"Worth","year":"2024","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.cct.2025.108078_bb0085","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13075-019-1879-x","volume":"21","author":"Taylor","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.cct.2025.108078_bb0090","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S2213-2600(21)00460-4","article-title":"Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial","volume":"10","author":"Fisher","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.cct.2025.108078_bb0095","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1136\/annrheumdis-2021-221865","article-title":"Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"81","author":"Cid","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cct.2025.108078_bb0100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/art.40323","article-title":"A randomized phase IIb study of Mavrilimumab and Golimumab in rheumatoid arthritis","volume":"70","author":"Weinblatt","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.cct.2025.108078_bb0105","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/art.40420","article-title":"Mavrilimumab, a fully human granulocyte-macrophage colony-stimulating factor receptor \u03b1 monoclonal antibody: long-term safety and efficacy in patients with rheumatoid arthritis","volume":"70","author":"Burmester","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.cct.2025.108078_bb0110","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.cct.2025.108078_bb0115","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-019-0096-x","article-title":"Sarcoidosis","volume":"5","author":"Grunewald","year":"2019","journal-title":"Nat Rev Dis Primers."},{"key":"10.1016\/j.cct.2025.108078_bb0120","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1080\/17476348.2019.1655401","article-title":"New concepts in the pathogenesis of sarcoidosis","volume":"13","author":"Bennett","year":"2019","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.cct.2025.108078_bb0125","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1146\/annurev-immunol-032712-100022","article-title":"The formation and function of granulomas","volume":"36","author":"Pag\u00e1n","year":"2018","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cct.2025.108078_bb0130","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.immuni.2016.10.026","article-title":"GM-CSF: from growth factor to central mediator of tissue inflammation","volume":"45","author":"Becher","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.cct.2025.108078_bb0135","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/DAD.0b013e3182a730cb","article-title":"Expression of notch signaling components in cutaneous foreign body and sarcoidal granulomas and fusing macrophages","volume":"36","author":"Rangel","year":"2014","journal-title":"Am. J. Dermatopathol."},{"key":"10.1016\/j.cct.2025.108078_bb0140","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1189\/jlb.1204723","article-title":"Disruption of granulocyte macrophage-colony stimulating factor production in the lungs severely affects the ability of mice to control Mycobacterium tuberculosis infection","volume":"77","author":"Gonzalez-Juarrero","year":"2005","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.cct.2025.108078_bb0145","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMra2101555","article-title":"Challenges of sarcoidosis and its management","volume":"385","author":"Drent","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2025.108078_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103120","article-title":"Circulating T cells in sarcoidosis have an aberrantly activated phenotype that correlates with disease outcome","volume":"149","author":"Miedema","year":"2024","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.cct.2025.108078_bb0155","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1378\/chest.111.3.623","article-title":"Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy","volume":"111","author":"Gottlieb","year":"1997","journal-title":"Chest"},{"key":"10.1016\/j.cct.2025.108078_bb0160","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1080\/14656566.2024.2377714","article-title":"The current state-of-the-art in pharmacotherapy for pulmonary sarcoidosis","volume":"25","author":"Mata Salvador","year":"2024","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.cct.2025.108078_bb0165","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejim.2022.12.003","article-title":"Role of anti-tumor necrosis factor-alpha agents in treatment of sarcoidosis: a meta-analysis","volume":"109","author":"Rezaee","year":"2023","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.cct.2025.108078_bb0170","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.cct.2025.108078_bb0175","first-page":"121","article-title":"Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis","volume":"26","author":"Park","year":"2009","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.cct.2025.108078_bb0180","first-page":"60","article-title":"Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial","volume":"17","author":"Baughman","year":"2000","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.cct.2025.108078_bb0185","first-page":"198","article-title":"Use of fluticasone in acute symptomatic pulmonary sarcoidosis","volume":"19","author":"Baughman","year":"2002","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.cct.2025.108078_bb0190","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1183\/09031936.00000914","article-title":"Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis","volume":"44","author":"Judson","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.cct.2025.108078_bb0195","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s41030-023-00222-2","article-title":"Results from a phase 4, multicenter, randomized, double-blind, placebo-controlled study of repository Corticotropin injection for the treatment of pulmonary sarcoidosis","volume":"9","author":"Mirsaeidi","year":"2023","journal-title":"Pulm Ther."},{"key":"10.1016\/j.cct.2025.108078_bb0200","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2025.108078_bb0205","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1056\/NEJMra071714","article-title":"Sarcoidosis","volume":"357","author":"Iannuzzi","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2025.108078_bb0210","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1183\/09031936.00088612","article-title":"Imaging the inflammatory activity of sarcoidosis","volume":"41","author":"Keijsers","year":"2013","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.cct.2025.108078_bb0215","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1513\/AnnalsATS.202208-731ED","article-title":"Pulmonary sarcoidosis: beyond restriction and forced vital capacity","volume":"20","author":"Obi","year":"2023","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.cct.2025.108078_bb0220","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12890-020-01290-9","article-title":"Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study","volume":"20","author":"Kahlmann","year":"2020","journal-title":"BMC Pulm. Med."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714425002721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714425002721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:55:22Z","timestamp":1787925322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714425002721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":44,"alternative-id":["S1551714425002721"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2025.108078","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design of RESOLVE Lung, a multinational Phase 2, randomized, placebo-controlled trial of the anti-GM-CSF monoclonal antibody namilumab in patients with chronic pulmonary sarcoidosis","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2025.108078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108078"}}